PL2370440T3 - Bezwodnik 2-amino-2-(hydroksymetylo)-1,3-propanodiolu 8-chloru-3-pentylo-3,7-dihydro-1H-puryno-2,6-dionu do leczenia chorób - Google Patents

Bezwodnik 2-amino-2-(hydroksymetylo)-1,3-propanodiolu 8-chloru-3-pentylo-3,7-dihydro-1H-puryno-2,6-dionu do leczenia chorób

Info

Publication number
PL2370440T3
PL2370440T3 PL09832421T PL09832421T PL2370440T3 PL 2370440 T3 PL2370440 T3 PL 2370440T3 PL 09832421 T PL09832421 T PL 09832421T PL 09832421 T PL09832421 T PL 09832421T PL 2370440 T3 PL2370440 T3 PL 2370440T3
Authority
PL
Poland
Prior art keywords
anhydrate
dione
purine
propanediol
dihydro
Prior art date
Application number
PL09832421T
Other languages
English (en)
Polish (pl)
Inventor
Holly Esken
Beth Adams Norton
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of PL2370440T3 publication Critical patent/PL2370440T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09832421T 2008-12-08 2009-12-07 Bezwodnik 2-amino-2-(hydroksymetylo)-1,3-propanodiolu 8-chloru-3-pentylo-3,7-dihydro-1H-puryno-2,6-dionu do leczenia chorób PL2370440T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12059608P 2008-12-08 2008-12-08
PCT/US2009/066941 WO2010068581A1 (en) 2008-12-08 2009-12-07 Novel compounds
EP09832421.3A EP2370440B1 (en) 2008-12-08 2009-12-07 8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione 2-amino-2-(hydroxymethyl)-1,3-propanediol anhydrate for the treatment of diseases

Publications (1)

Publication Number Publication Date
PL2370440T3 true PL2370440T3 (pl) 2015-05-29

Family

ID=42243044

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09832421T PL2370440T3 (pl) 2008-12-08 2009-12-07 Bezwodnik 2-amino-2-(hydroksymetylo)-1,3-propanodiolu 8-chloru-3-pentylo-3,7-dihydro-1H-puryno-2,6-dionu do leczenia chorób

Country Status (22)

Country Link
US (3) US9163024B2 (enExample)
EP (1) EP2370440B1 (enExample)
JP (1) JP5666464B2 (enExample)
KR (1) KR101743783B1 (enExample)
CN (1) CN102245606B (enExample)
AU (1) AU2009324811B2 (enExample)
BR (1) BRPI0922134A2 (enExample)
CA (1) CA2746316C (enExample)
CY (1) CY1116032T1 (enExample)
DK (1) DK2370440T3 (enExample)
EA (1) EA020037B1 (enExample)
ES (1) ES2527354T3 (enExample)
HR (1) HRP20150026T1 (enExample)
IL (1) IL213032A (enExample)
MX (1) MX2011006022A (enExample)
PL (1) PL2370440T3 (enExample)
PT (1) PT2370440E (enExample)
RS (1) RS53777B1 (enExample)
SI (1) SI2370440T1 (enExample)
SM (1) SMT201500012B (enExample)
WO (1) WO2010068581A1 (enExample)
ZA (1) ZA201103397B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1781657T3 (da) * 2004-02-14 2013-06-10 Glaxosmithkline Ip Dev Ltd Medikamenter med hm74a-receptor aktivitet
SI1912991T1 (sl) 2005-08-10 2011-03-31 Glaxosmithkline Llc One Franklin Plaza Derivati ksantina kot selektivni hm74a agonisti
EP2854526B1 (en) * 2012-03-22 2018-04-25 vTv Therapeutics LLC Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof
CN121219290A (zh) 2023-02-27 2025-12-26 珊顿医药科技新加坡公司 化合物8-氯-3-戊基-3,7-二氢-1h-嘌呤-2,6-二酮的晶型及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657327A (en) * 1970-06-01 1972-04-18 Upjohn Co Prostaglandin salts of tris(hydroxymethyl)aminomethane
US4647585A (en) * 1984-11-08 1987-03-03 E. R. Squibb & Sons, Inc. Bicycloheptane substituted ethers
JP2003534238A (ja) * 1999-12-15 2003-11-18 スミスクライン・ビーチャム・コーポレイション シス−４−シアノ−４−［３−（シクロペンチルオキシ）−４−メトキシフェニル］シクロヘキサン−１−カルボン酸の塩。
US20030013905A1 (en) 2002-06-10 2003-01-16 Huang Guishu Kris Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid
DK1781657T3 (da) * 2004-02-14 2013-06-10 Glaxosmithkline Ip Dev Ltd Medikamenter med hm74a-receptor aktivitet
GB0423568D0 (en) * 2004-10-22 2004-11-24 Smithkline Beecham Corp Novel compounds
US20090209561A1 (en) 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
SI1912991T1 (sl) 2005-08-10 2011-03-31 Glaxosmithkline Llc One Franklin Plaza Derivati ksantina kot selektivni hm74a agonisti
GB0516464D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds

Also Published As

Publication number Publication date
CA2746316A1 (en) 2010-06-17
US20170027945A1 (en) 2017-02-02
JP5666464B2 (ja) 2015-02-12
CN102245606B (zh) 2014-08-20
EA201170783A1 (ru) 2011-12-30
JP2012511028A (ja) 2012-05-17
KR20110097816A (ko) 2011-08-31
CA2746316C (en) 2017-01-03
US9163024B2 (en) 2015-10-20
AU2009324811A1 (en) 2011-06-23
US20150366870A1 (en) 2015-12-24
SI2370440T1 (sl) 2015-02-27
RS53777B1 (sr) 2015-06-30
IL213032A0 (en) 2011-07-31
AU2009324811B2 (en) 2013-01-24
CY1116032T1 (el) 2017-01-25
DK2370440T3 (en) 2014-12-08
ES2527354T3 (es) 2015-01-22
IL213032A (en) 2015-02-26
EP2370440A4 (en) 2012-05-30
CN102245606A (zh) 2011-11-16
EA020037B1 (ru) 2014-08-29
EP2370440A1 (en) 2011-10-05
MX2011006022A (es) 2011-06-28
US20110251218A1 (en) 2011-10-13
BRPI0922134A2 (pt) 2015-08-18
EP2370440B1 (en) 2014-11-12
PT2370440E (pt) 2015-01-14
KR101743783B1 (ko) 2017-06-05
WO2010068581A1 (en) 2010-06-17
ZA201103397B (en) 2012-01-25
SMT201500012B (it) 2015-05-03
HRP20150026T1 (hr) 2015-02-13

Similar Documents

Publication Publication Date Title
CY2017042I1 (el) Ενωσεις πυρρολοπυριμιδινης ως αναστολεις cdk
DK2300443T3 (da) Triazolderivater, der er anvendelige til behandling af sygdomme
BRPI0925059A2 (pt) Pirimidina substituída de compostos de purina como quinase(s) inibidoras.
BR112014028395A2 (pt) derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer
IL211509A0 (en) Compounds for the treatment of hepatitis c
DK2483255T3 (da) Oxazinderivater samt deres anvendelse ved behandling af neurologiske lidelser
BRPI0811065A2 (pt) Indazóis 5-heteroaril substituídos como inibidores de quinase
IL208350A0 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
DOP2011000388A (es) Carboxamidas 5-fenilo-[1,2,4] triazolo [1,5-a] piridina-2-il como inhibidores jak
ZA201003110B (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
BR112012000792A2 (pt) compostos heterocíclicos como inibidores de autotaxina
ZA201006752B (en) Spiro-indole derivatives for the treatment of parasitic disease
IL211556A0 (en) Process for the preparation of pramlintide
BR112012018830A2 (pt) compostos heterocíclicos como inibidores de quinase de janus
EP2374799A4 (en) PROCESS FOR PREPARING 4- (1-HYDROXY-1-METHYLETHYL) -2-PROPYLIMIDAZOLE-5-CARBOXYLATE
EP1971589A4 (en) PROCESS FOR PREPARING 3-HYDROXYTETRAHYDROFURAN BY MEANS OF CYCLODE HYDROGENATION
PL2370440T3 (pl) Bezwodnik 2-amino-2-(hydroksymetylo)-1,3-propanodiolu 8-chloru-3-pentylo-3,7-dihydro-1H-puryno-2,6-dionu do leczenia chorób
BR112012003420A2 (pt) método de fabricação de calçado usando primer multifuncional
NO20075659L (no) Framgangsmate for tilvirkning av fyringsprodukt, samt fyringsprodukt
TH0901000513A (th) อนุพันธ์สไปโรไซคลิค แอมีดสำหรับการรักษาโรคปอด
TH0801003323A (th) สารประกอบสำหรับการบำบัดโรคตับอักเสบ c
ITBA20070031U1 (it) Puntale per calzature di sicurezza